Skip to main content
. Author manuscript; available in PMC: 2024 Nov 29.
Published in final edited form as: Mol Pharm. 2023 Aug 8;20(9):4629–4639. doi: 10.1021/acs.molpharmaceut.3c00360

Figure 7.

Figure 7.

Biodistribution of [89Zr]Zr-DFO-2Rs15d in HER2-positive and HER2-negative tumor-bearing mice. Full body biodistribution at (A) 24 h and (B) 72 h shows high kidney radioactivity levels with modest liver, spleen, and femur uptake. (C) HER2-positive tumors had significantly higher tumor uptake and (D) tumor-to-blood ratios of [89Zr]Zr-DFO-2Rs15d compared to HER2-negative tumors at both time points. (n = 4 for all groups). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.